Economic burden and loss of quality of life from dry eye disease in Canada
- PMID: 34604535
- PMCID: PMC8444260
- DOI: 10.1136/bmjophth-2021-000709
Economic burden and loss of quality of life from dry eye disease in Canada
Abstract
Objective: To describe the direct and indirect cost estimates of dry eye disease (DED), stratified by disease severity, and the impact of DED on quality of life (QoL) in Canadian patients.
Methods and analysis: A prospective, multicentre, observational, cross-sectional study was conducted at six sites across Canada. Eligible patients completed a 20 min survey on demography, general health, disease severity, QoL and direct (resource utilisation and out-of-pocket expenses for the past 3-24 months) and indirect costs (absenteeism and presenteeism based on Work Productivity and Activity Impairment questionnaire responses). Subgroup analyses were performed according to DED severity and presence of Sjögren's syndrome.
Results: Responses from 146 of 151 participants were included in the analysis. DED was rated as moderate or severe by 19.2% and 69.2% of patients, respectively. Total mean annual costs of DED were $C24 331 (Canadian dollars) per patient and increased with patient-reported disease severity. Mean (standard deviation [SD]) indirect costs for mild, moderate and severe disease were $C5961 ($C6275), $C16 525 ($C11 607), and $C25 485 ($C22,879), respectively. Mean (SD) direct costs were $C958 ($C1216), $C1303 ($C1574) and $C2766 ($C7161), respectively. QoL scores were lowest in patients with Sjögren's syndrome (8.2% of cohort) and those with severe DED.
Conclusion: This study provides important insights into the negative impact of DED in a Canadian setting. Severe DED was associated with higher direct and indirect costs and lower QoL compared with those with mild or moderate disease. Increased costs and poorer QoL were also evident for patients with DED plus Sjögren's syndrome versus DED alone.
Keywords: clinical trial; ocular surface.
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: CC has been a consultant for Alcon, Allergan, Bausch+Lomb, Johnson & Johnson, Labtician, Santen, and Shire* and has received research support from Allergan, Bausch+Lomb and TearLab. SZ has received grant/research support from Shire* and honoraria/consulting fees from Allergan, Labtician, J&J, Santen, and Shire*. VM was a paid consultant to Shire* in connection with this study. JGB was an employee of Shire* at the time of the study and is a current employee of Novartis. CLP has been a consultant for Alcon Canada, Innova Medical, Shire*, Novartis and Bausch+Lomb Canada. *A Takeda company.
Figures




Similar articles
-
Relationship between clinical parameters and quality of life in primary Sjögren's Syndrome: a prospective study.Eye (Lond). 2023 Sep;37(13):2685-2692. doi: 10.1038/s41433-023-02386-2. Epub 2023 Jan 19. Eye (Lond). 2023. PMID: 36658430 Free PMC article.
-
The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care.J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S34-S41. doi: 10.1093/jcag/gwy050. Epub 2018 Nov 2. J Can Assoc Gastroenterol. 2019. PMID: 31294383 Free PMC article.
-
The Enduring Experience in Dry Eye Diagnosis: A Non-Interventional Study Comparing the Experiences of Patients Living With and Without Sjögren's Syndrome.Ophthalmol Ther. 2021 Jun;10(2):321-335. doi: 10.1007/s40123-021-00341-6. Epub 2021 Apr 1. Ophthalmol Ther. 2021. PMID: 33792865 Free PMC article.
-
Prevalence, burden, and pharmacoeconomics of dry eye disease.Am J Manag Care. 2008 Apr;14(3 Suppl):S102-6. Am J Manag Care. 2008. PMID: 18452369 Review.
-
Sjogren's syndrome from the perspective of ophthalmology.Clin Immunol. 2017 Sep;182:55-61. doi: 10.1016/j.clim.2017.04.017. Epub 2017 May 2. Clin Immunol. 2017. PMID: 28476437 Review.
Cited by
-
Dry eye disease severity and impact on quality of life in type II diabetes mellitus.Front Med (Lausanne). 2023 Feb 27;10:1103400. doi: 10.3389/fmed.2023.1103400. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36923012 Free PMC article.
-
Social Determinants of Dry Eye in the United States: A Systematic Review.Am J Ophthalmol. 2024 May;261:36-53. doi: 10.1016/j.ajo.2024.01.015. Epub 2024 Jan 17. Am J Ophthalmol. 2024. PMID: 38242339 Free PMC article.
-
An Assessment of the Ocular Toxicity of Two Major Sources of Environmental Exposure.Int J Environ Res Public Health. 2024 Jun 15;21(6):780. doi: 10.3390/ijerph21060780. Int J Environ Res Public Health. 2024. PMID: 38929026 Free PMC article.
-
Recombinant human nerve growth factor (cenegermin) for moderate-to-severe dry eye: phase II, randomized, vehicle-controlled, dose-ranging trial.BMC Ophthalmol. 2024 Jul 17;24(1):290. doi: 10.1186/s12886-024-03564-w. BMC Ophthalmol. 2024. PMID: 39020305 Free PMC article. Clinical Trial.
-
The economic burden of diagnostic uncertainty on rare disease patients.BMC Health Serv Res. 2024 Nov 12;24(1):1388. doi: 10.1186/s12913-024-11763-w. BMC Health Serv Res. 2024. PMID: 39533273 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Miscellaneous